



PATIENT NAME TESTING, PARDP_ABNORMAL				ORDER NUMBER M311000200
PATIENT ID SA00154795	DATE OF BIRTH 08/08/2001	AGE 21 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:31 PM	REPORTED 10/14/2022, 4:43 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154795 CLIENT MRN SA00154795

TEST DESCRIPTION

Evaluation of 94 genes associated with Parkinson disease

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
SOD1 (NM_000454.4)	c.112G>A p.Gly38Arg (p.G38A) chr21(GRCh37):g.33036142G>A	heterozygous	PATHOGENIC

The following heterozygous PATHOGENIC variant was detected:

SOD1 (NM_000454.4), chr21(GRCh37):g.33036142G>A, c.112G>A, p.Gly38Arg (p.G38A)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

SOD1 c.112G>A (p.Gly38Arg), PATHOGENIC

The heterozygous c.112G>A (p.Gly38Arg) missense variant in the SOD1 gene (MIM:147450) is classified as pathogenic. Pathogenic variants in the SOD1 gene have been associated with autosomal dominant and autosomal recessive forms of amyotrophic lateral sclerosis and autosomal recessive spastic tetraplegia and axial hypotonia. This variant has been reported in both sporadic and familial cases of amyotrophic lateral sclerosis (1-6). Furthermore, functional studies have shown that this variant impacts mitochondrial function, activates apoptotic pathways, and leads to an amyotrophic lateral sclerosis phenotype in mouse models (7-10). This variant is absent from large control databases (11,12). Due to the multiple established inheritance patterns for the condition(s) associated with this gene, this result is supportive of either carrier status for, or a diagnosis of, a SOD1-related disorder for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.

REFERENCES:

1) Tsai PC, Liao YC, Jih KY, Soong BW, Lin KP, Lee YC. Genetic analysis of ANXA11 variants in a Han Chinese cohort



1-800-533-1710

Parkinson Disease Gene Panel

PARDP

PATIENT NAME TESTING, PARDP_ABNORMAL				ORDER NUMBER M311000200
PATIENT ID SA00154795	DATE OF BIRTH 08/08/2001	AGE 21 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:31 PM	REPORTED 10/14/2022, 4:43 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154795 CLIENT MRN SA00154795

with amyotrophic lateral sclerosis in Taiwan. Neurobiol Aging. 2018;72:188.e1-188.e2.

doi:10.1016/j.neurobiolaging.2018.07.002 (PMID 30054183)

2) Chen LX, Xu HF, Wang PS, Yang XX, Wu ZY, Li HF. SOD1 Mutation Spectrum and Natural History of ALS Patients in a 15-Year Cohort in Southeastern China. Front Genet. 2021;12:746060. Published 2021 Oct 14.

doi:10.3389/fgene.2021.746060 (PMID 34721532)

3) Millicamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47(8):554-560.

doi:10.1136/jmg.2010.077180 (PMID 20577002)

4) Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41(2):210-221. doi:10.1002/ana.410410212 (PMID 9029070)

5) Brown JA, Min J, Staropoli JF, et al. SOD1, ANG, TARDBP and FUS mutations in amyotrophic lateral sclerosis: a United States clinical testing lab experience. Amyotroph Lateral Scler. 2012;13(2):217-222.

doi:10.3109/17482968.2011.643899 (PMID 22292843)

6) Gamez J, Corbera-Bellalta M, Nogales G, et al. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1? J Neurol Sci. 2006;247(1):21-28.

doi:10.1016/j.jns.2006.03.006 (PMID 16674979)

7) Ferri A, Cozzolino M, Crosio C, et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U S A. 2006;103(37):13860-13865. doi:10.1073/pnas.0605814103 (PMID 16945901)

8) Cousse E, De Smet P, Bogaert E, et al. G37R SOD1 mutant alters mitochondrial complex I activity, Ca(2+) uptake and ATP production. Cell Calcium. 2011;49(4):217-225. doi:10.1016/j.ceca.2011.02.004 (PMID 21388680)

9) Ferri A, Nencini M, Casciati A, et al. Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells. FASEB J. 2004;18(11):1261-1263. doi:10.1096/fj.03-1199fje (PMID 15208263)

10) Filali M, Lalonde R, Rivest S. Sensorimotor and cognitive functions in a SOD1(G37R) transgenic mouse model of amyotrophic lateral sclerosis. Behav Brain Res. 2011;225(1):215-221. doi:10.1016/j.bbr.2011.07.034 (PMID 21816178)

11) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 1999;9:677-679 (PMID 10447503)

12) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS, and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID PARDP) for details regarding genes with regions not routinely covered.



1-800-533-1710

Parkinson Disease Gene Panel

PARDP

PATIENT NAME TESTING, PARDP_ABNORMAL				ORDER NUMBER M311000200
PATIENT ID SA00154795	DATE OF BIRTH 08/08/2001	AGE 21 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:31 PM	REPORTED 10/14/2022, 4:43 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00154795
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00154795

GENES ANALYZED

ADORA1, AHS1, ANG, ANO3, APP, ATP13A2, ATP1A3, ATP6AP2, ATP7B, C19orf12, CHCHD2, CHMP2B, CLN3, CP, CSF1R, CYP27A1, DCAF17, DCTN1, DDC, DNAJB2, DNAJC12, DNAJC13, DNAJC6, DNM1L, EIF4G1, FBXO7, FTL, FUS, GBA, GCH1, GIGYF2, GRN, HTRA2, KIF5A, LRP10, LRRK2, LYST, MAPT, OPTN, PANK2, PARK7, PDE10A, PDE8B, PDGFB, PDGFRB, PEX1, PINK1, PLA2G6, PLD3, PODXL, POLG, POLG2, PRKAR1B, PRKN, PRKRA, PRRT2, PSEN1, PSEN2, PTRHD1, RAB29, RAB39B, RIC3, SIGMAR1, SLC18A2, SLC20A2, SLC30A10, SLC39A14, SLC6A3, SNCA, SNCB, SOD1, SPG11, SPR, SQSTM1, SYNJ1, TAF1, TAF15, TARDBP, TENM4, TH, THAP1, TMEM230, TOR1A, TUBA4A, TWNK, UBQLN2, UCHL1, UNC13A, VCP, VPS13A, VPS13C, VPS35, WDR45 and XPR1

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Parkinson Disease Gene Panel in the Special Instructions section of the Test Catalog for the



1-800-533-1710

Parkinson Disease Gene Panel

PARDP

PATIENT NAME TESTING, PARDP_ABNORMAL				ORDER NUMBER M311000200
PATIENT ID SA00154795	DATE OF BIRTH 08/08/2001	AGE 21 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:31 PM	REPORTED 10/14/2022, 4:43 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00154795
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00154795

most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID PARDP) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Niu, Zhiyv, Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE, II MD, PhD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905